Targeted radiation melanoma treatment with or without nivolumab
Treatments studied
Part of Cancer, Skin clinical trials.
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and able to understand the study and follow its visits and procedures
- Your melanoma is advanced (stage III or IV) and cannot be removed with surgery, or it has come back
- Your cancer has progressed after at least one approved treatment for advanced melanoma
- A special scan shows melanoma tumors take up the study’s radioactive-target material (on PET or SPECT imaging)
- You have measurable disease on scans and can lie still for up to 2 hours for imaging
- Your overall health and blood/organ tests are acceptable, and you can safely avoid pregnancy for at least 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, for people with melanoma that cannot be removed by surgery or has spread. The treatment aims to help the immune system fight the cancer more effectively.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.